TMDX · TransMedics Group, Inc.
$83.45
-0.62 (-0.74%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$2.96B
Shares
34.68M
Volume · Sep 30
566.81K
Avg daily vol (3M)
812.94K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$83.45
Open$84.87
Day$81.55–84.87
52W close$62.04–150.42
Avg vol 30d689K
Short int8.0M · 23.0% float · 10.7d
Short vol47%
Last earningsAug 4, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 5 wks
filed Aug 4, 2026
call held May 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$668.47M
Trailing 12 months
Net income (TTM)
$151.70M
Trailing 12 months
Revenue growth YoY
+20.7%
Year over year
Operating margin
12.2%
Trailing 12 months
P / E (TTM)
21.8
Trailing earnings · reciprocal yield 4.6%
FCF yield
2.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.4%
Year over year · more shares
Price change (1Y)
-25.4%
Trailing year
Short interest
23.0%
Latest settlement · 10.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
−2%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
24%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
−24%
trailing
YTD return
−31%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $85 › 200d $100 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +68 funds added
Insider flow
Accumulating
Net +$109.1K over 90 days · 0% sells
Short interest
Falling
23.01% of float · ▼ -1.3% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
382 holders — mid 3-yr range
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+37%
Y/Y
Gross margin
60%
expanding
EPS growth
+382%
Y/Y
Free cash flow
$133.6M
Balance sheet
$13.4M
net debt
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Revenue guidance
· full year 2026
Initiated
$727M – $757M
prior FY $605.49M
midpoint +22.5% Y/Y
Guided vs delivered
· last 4 settled
Full year 2024 revenue
full year 2024
guided $425M – $445M
$441.54M
In line
Full year 2023 revenue
full year 2023
guided $222M – $230M
$241.62M
Beat +6.9%
Q4 revenue
Q4 2021
guided $7M – $8M
$9.67M
Beat +28.9%
Full year net revenue
full year 2021
guided $27.6M – $28.6M
$30.26M
Beat +7.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
24%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $85 › 200d $100 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +68 funds added
Insider flow
Accumulating
Net +$109.1K over 90 days · 0% sells
Short interest
Falling
23.01% of float · ▼ -1.3% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
382 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $62
Now $83 · 24%
Range high $150
vs 200-day avg -17%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TMDX
this stock
TransMedics Group, Inc.
|
$2.96B | -31.4% | +37.1% | — | 23.0% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TMDX | -4.1% | +1.5% | -23.6% | -1.7% | -31.4% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -3.4% | +1.4% | -35.8% | -1.1% | -43.2% |